Introduction & Objective: Recurrent severe hypoglycemic events (SHE) are associated with impaired awareness of hypoglycemia (IAH). This study describes the demographic and clinical characteristics of adults with type 1 diabetes (T1D) and SHE/IAH.

Methods: Adult (≥18 years) continuous glucose monitor (CGM) users from the T1D Exchange Registry with self-reported T1D diagnosis ≥5 years completed an online survey with clinical and demographic characteristics. SHE cohorts were created based on SHE frequency in the past 12 months and the presence/absence of IAH (Modified Gold Score): problematic SHE (2+ SHE/IAH-; 1+ SHE/IAH+) and no SHE (0 SHE/IAH+; 0 SHE/IAH-). Participant characteristics were descriptively summarized (mean, standard deviation [SD]).

Results: A total of 1,847 T1D CGM users responded. The problematic SHE cohort (n=375) compared with the no SHE cohort (n=1,033) were older (age 49.0 vs. 45.6 years), more racially diverse (86.4% vs. 92.7% Caucasian), had lower levels of employment (58.4% vs. 71.2%), increased report of lower income <$50,000 (25.1% vs. 16.9%), and more often reported Medicaid as their primary health insurance (10.4% vs. 3.1%). The problematic SHE cohort reported longer duration of T1D (31.9 [SD 16.0] vs. no SHE 28.6 [SD 14.8]), lower insulin pump use (78.4% vs. 85.9%), slightly higher recent HbA1c (6.9 [SD 1.1] vs. 6.6 [SD 0.9]), with more participants with HbA1c ≥7% (42.4% vs. 31.3%). More T1D-related complications were reported in the problematic SHE vs. no SHE cohort (retinopathy 28.3% vs. 21.5%; neuropathy 24.5% vs. 10.5%; nephropathy 8.3% vs. 4.5%; gastroparesis 19.5% vs. 6.5%; and cardiovascular disease 12.5% vs. 5.5%). Based on BMI calculated from reported height and weight, >60% of participants were overweight or obese across all cohorts.

Conclusion: Findings suggest those who experience SHE have higher clinical burden and lower socioeconomic status, highlighting the need for innovative approaches to management for these individuals.

Disclosure

P. Callahan: Employee; Vertex Pharmaceuticals Incorporated. A. Boateng-Kuffour: Employee; Vertex Pharmaceuticals Incorporated. K. Chandarana: Employee; Vertex Pharmaceuticals Incorporated. Stock/Shareholder; Vertex Pharmaceuticals Incorporated, Novo Nordisk, Eli Lilly and Company. T. Gupta: Employee; Vertex Pharmaceuticals Incorporated. L. Chen: None. C.S. Kelly: None. H. Nguyen: None. K.S.M. Chapman: None. E.M. Cornelius: None. W. Wolf: None. W.H. Polonsky: Research Support; Abbott Diagnostics, Dexcom, Inc. Consultant; Eli Lilly and Company, Sanofi. Advisory Panel; embecta. Consultant; Vertex Pharmaceuticals Incorporated. Advisory Panel; 9am Health.

Funding

Vertex Pharmaceuticals Incorporated

Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at http://www.diabetesjournals.org/content/license.